Molecular Genetics of Drug Addiction and Related Co Morbidities (R01) | Apply Online

Opportunity Summary:

The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01) funding opportunity (PA-11-026) is an NIH discretionary research grant program focused on uncovering the genetic and genomic factors that contribute to drug addiction risk and to differences in how people respond to treatment. The central aim is to support research that identifies and/or validates chromosomal regions (loci) and specific gene variants associated with vulnerability to addiction, while also generating knowledge that could help predict treatment responsiveness. In practice, this means projects can range from discovering new genetic associations to confirming previously reported signals in independent samples, with an emphasis on findings that can move the field toward more biologically grounded risk models and, eventually, more individualized prevention and treatment approaches.

A key priority in this announcement is the use of intermediate phenotypes, often called endophenotypes, to bridge the gap between broad clinical diagnoses and underlying biology. Rather than studying addiction outcomes alone, applicants are encouraged to examine measurable traits linked to addiction vulnerability and progression, such as neurocognitive measures (for example, impulsivity or inhibitory control), stress reactivity, reward sensitivity, neuroimaging traits, electrophysiological markers, or other quantifiable behavioral and biological indicators. The idea is that these intermediate traits may map more directly onto genetic mechanisms than a complex clinical endpoint, potentially improving the ability to detect meaningful genetic effects and clarify how genetic variation contributes to addiction and related co-morbid conditions.

The FOA explicitly welcomes a wide range of genetic, genomic, and computational strategies. Acceptable approaches include classic and modern study designs such as linkage analysis, linkage disequilibrium mapping, case-control studies, family-based designs, and other large-scale genomic methods. It also encourages projects that integrate primary study data with external resources, including the use of existing databases and datasets that can strengthen substance use genetics and genomics research through replication, meta-analysis, cross-cohort comparisons, or functional annotation. This emphasis signals that both data generation and sophisticated data integration/analysis are within scope, especially when they increase rigor, reproducibility, and interpretability of genetic findings.

The types of populations and models supported are broad. Data may come from the general population, targeted or special populations, recently admixed populations (where ancestry patterns can be informative for gene mapping when handled carefully), and non-human or animal models. The inclusion of animal models highlights NIH interest in mechanistic follow-up and experimental leverage, such as testing how candidate genes influence drug-related behaviors, neural circuitry, or molecular pathways in controlled settings. Overall, the FOA is structured to support discovery across diverse samples and to encourage designs that can address both statistical association and biological plausibility.

Applicants are also encouraged to incorporate more complex etiologic frameworks when appropriate, including gene-by-gene interactions (epistasis), gene-by-environment interactions (how genetic risk varies with exposures such as stress, trauma, social context, or drug availability), and gene-by-environment-by-development interactions (how these relationships change across developmental stages, such as adolescence versus adulthood). Pharmacogenetics is specifically highlighted as well, reflecting interest in genetic predictors of medication response, side effects, dosing needs, or treatment outcomes in substance use disorders. Collectively, these encouraged components underscore an expectation that addiction risk and treatment response are multifactorial, and that competitive projects may explicitly model interacting influences rather than treating genetic effects as isolated contributors.

Administratively, this opportunity is an R01 research project grant under the NIH umbrella and is tied to CFDA 93.279 (Drug Abuse and Addiction Research Programs). It does not require cost sharing or matching. Eligible applicants are extensive and include public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status, depending on category), for-profit organizations (including those other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district governments), as well as tribal governments and tribal organizations. The eligibility list also includes a wide range of mission-driven and capacity-building institution types such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based and community-based organizations, U.S. territories/possessions, regional organizations, and even non-U.S. entities (foreign organizations), reflecting NIH’s broad applicant base for biomedical research.

In terms of timing, the opportunity was posted on November 9, 2010, with administrative record dates showing creation on December 10, 2013, and an archive date of January 10, 2014. The original closing date was listed as January 7, 2014, with a current closing date shown as December 10, 2013, indicating that the listing is now archived and no longer open for new submissions under that specific announcement. The agency contact for access or linking issues is the NIH Office of Extramural Research webmaster (FBOWebmaster@OD.NIH.GOV), and the full announcement was hosted on the NIH grants guide page associated with PA-11-026.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Advances in Patient Safety through Simulation Research (R18)

Previous opportunity: Migratory Bird Joint Ventures Playa Lakes Joint Venture Partnership Annual Base Operations

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 11 026

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 11 026) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 11 026", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.